Harper Molly

Insider profile

Performance

Overall performance
2.5

Performance over holding periods
2.5
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 60% 68% 82%
Transactions
7 0% Buy
34 71% Buy
47 69% Buy
Harper Molly's trades of Catalyst Pharmaceuticals Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2025-12-16 2025-12-12 S Sale
63,325 -4.2%
275.42
US$517,603
63,325 -4.2% 275.42 US$517,603
2025-12-16 2025-12-12 S Sale
94,777 +4.4%
21.87
US$1,310,416
94,777 +4.4% 21.87 US$1,310,416
2025-12-16 2025-12-12 S Sale
65,359 +5.0%
146.38
US$2,691,043
65,359 +5.0% 146.38 US$2,691,043
2025-12-12 2025-12-12 PrS Proposed sale
26,746
23.25
US$621,929
26,746 23.25 US$621,929
2024-11-29 2024-11-27 S Sale
17,500 -100.0%
22.00
US$385,000
17,500 -100.0% 22.00 US$385,000
2024-11-27 2024-11-27 PrS Proposed sale
17,500
22.00
US$385,000
17,500 22.00 US$385,000
2024-06-05 2024-06-03 S Sale
5,333 -100.0%
16.30
US$86,949
5,333 -100.0% 16.30 US$86,949
2024-06-03 2024-06-03 PrS Proposed sale
5,333
16.30
US$86,952
5,333 16.30 US$86,952
2023-12-19 2023-12-15 S Sale
10,000 -100.0%
14.37
US$143,700
10,000 -100.0% 14.37 US$143,700
2023-12-19 2023-12-15 S Sale
4,000 -100.0%
14.43
US$57,720
4,000 -100.0% 14.43 US$57,720
2023-12-15 2023-12-15 PrS Proposed sale
14,000
14.39
US$201,441
14,000 14.39 US$201,441